Tirilazad

Tirilazad

Clinical data
Other names	(8S,10S,13S,14S,16R,17S)-17-[2-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one
ATC code	N07XX01 (WHO)
Identifiers
IUPAC name (16α)-21-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]-16-methylpregna-1,4,9(11)-triene-3,20-dione
JSmol)	Interactive image
SMILES O=C(CN4CCN(c2nc(nc(N1CCCC1)c2)N3CCCC3)CC4)[C@H]6[C@H](C)C[C@H]5[C@H]8C(=C/C[C@@]56C)\[C@]/7(/C=C\C(=O)\C=C\7CC8)C
InChI InChI=1S/C38H52N6O2/c1-26-22-31-29-9-8-27-23-28(45)10-12-37(27,2)30(29)11-13-38(31,3)35(26)32(46)25-41-18-20-43(21-19-41)34-24-33(42-14-4-5-15-42)39-36(40-34)44-16-6-7-17-44/h10-12,23-24,26,29,31,35H,4-9,13-22,25H2,1-3H3/t26-,29-,31+,35-,37+,38+/m1/s1 Y Key:RBKASMJPSJDQKY-RBFSKHHSSA-N Y
NY (what is this?)  (verify)

Tirilazad is a drug that has been proposed to treat acute ischaemic stroke. When tested on animal models, tirilazad protects brain tissue, and reduces brain damage. However, the drug fails to treat, and even worsens a stroke when studied on a human being.^[1]

References